{"filing":{"accession_number":"0001193125-26-253709","cik":"0001645460","ticker":"CUE","company_name":"Cue Biopharma, Inc.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"d139032d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/d139032d8k.htm"},"events":[{"id":7484,"run_id":6576,"accession_number":"0001193125-26-253709","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.8,"summary":"On June 1, 2026, Cue Biopharma appointed Sumita Ray as Chief Legal \u0026 Compliance Officer and Corporate Secretary, Michael Meluzio as Vice President and Principal Accounting Officer, and Daniel Camardo and Viola Meehan as directors. The appointments represent material governance and executive leadership changes, including board restructuring from seven to five directors and committee assignments for the new board members.","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3600,"accession_number":"0001193125-26-253709","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses multiple executive and board-level appointments on June 1, 2026: Sumita Ray as Chief Legal \u0026 Compliance Officer and Corporate Secretary, Michael Meluzio as Vice President and Principal Accounting Officer, and Daniel Camardo and Viola Meehan as directors. While the section also includes four director resignations, the principal disclosed actions center on the new appointments filling key executive and governance roles. The material nature is evident from the senior positions involved (General Counsel, Principal Accounting Officer, board directors) and the board restructuring from seven to five directors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:19:08.021124+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3601,"accession_number":"0001193125-26-253709","item_number":"8.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses appointments of Mr. Camardo and Ms. Meehan to the Board of Directors, with subsequent committee assignments. While the Item 8.01 caption is \"Other Events,\" the substance is executive/director appointments, which are material governance changes affecting the composition of the board and its oversight committees.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:19:08.021124+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3600,"accession_number":"0001193125-26-253709","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses multiple executive and board-level appointments on June 1, 2026: Sumita Ray as Chief Legal \u0026 Compliance Officer and Corporate Secretary, Michael Meluzio as Vice President and Principal Accounting Officer, and Daniel Camardo and Viola Meehan as directors. While the section also includes four director resignations, the principal disclosed actions center on the new appointments filling key executive and governance roles. The material nature is evident from the senior positions involved (General Counsel, Principal Accounting Officer, board directors) and the board restructuring from seven to five directors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:19:08.021124+00:00","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-06-02"},{"id":3601,"accession_number":"0001193125-26-253709","item_number":"8.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses appointments of Mr. Camardo and Ms. Meehan to the Board of Directors, with subsequent committee assignments. While the Item 8.01 caption is \"Other Events,\" the substance is executive/director appointments, which are material governance changes affecting the composition of the board and its oversight committees.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:19:08.021124+00:00","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-06-02"}]}